21 CFR Part 11 Compliance Checklist for Pharma AI Tools

As the pharmaceutical industry increasingly integrates AI technologies into its operational landscape, ensuring compliance with existing regulatory frameworks becomes critically important. Among these regulations, 21 CFR Part 11 stands out as a vital standard governing electronic records and electronic signatures in FDA-regulated environments. For pharmaceutical companies and CDMOs in the DACH region and broader EU, this means adopting AI tools that comply with these stringent requirements. Below, we provide a practical compliance checklist specifically tailored for AI tools to help navigate and meet the challenges posed by 21 CFR Part 11.

Understand the Scope

21 CFR Part 11 applies to all records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted under any records requirements set forth by FDA regulations. For AI tools in pharma, this includes any computational model that generates data or interacts with systems that store regulatory data. Determine if your AI tool engages with these processes, and if so, ensure your systems are designed to comply with these requirements.

Electronic Records Management

AI tools must handle electronic records with the same integrity as traditional systems. Here are critical areas to consider:

• Identity Verification: Ensure that any AI-generated record can be traced back to verified users via secure login credentials.
• Record Accuracy: Implement mechanisms for maintaining record accuracy, completeness, and protecting against unauthorized changes.
• Audit Trails: Your AI system must generate secure, computer-generated, time-stamped audit trails that independently record the date and time of operator entries and actions.

Electronic Signatures

Electronic signatures must be as reliable and legal as traditional handwritten signatures. Ensure that AI tools facilitating electronic signatures meet the following criteria:

• Unique To One Individual: Ensure each electronic signature is unique to one individual and not reassigned.
• Verification: The signature must be able to be validated by a recognized authority.
• Signature Components: Electronic signature components and controls must be used only by their genuine owners, and a form of identification (such as a password or security token) must be implemented.

Data Integrity and AI

When integrating AI tools, it's vital to maintain data integrity, a core principle within 21 CFR Part 11:

• Backups and Retention: Ensure that backup and recovery procedures capture AI-generated data and its processing history correctly.
• Data Accessibility: Implement systems enabling only authorized personnel to access sensitive records or process data changes.
• Processing Safeguards: Protection against unauthorized changes must be in place, with a focus on maintaining the traceability of AI decisions.

Validation of AI Tools

Ensuring AI systems are validated for reliability, acceptability, and consistency is crucial. This involves:

• Performance Qualification: Ensure AI performance is regularly evaluated to verify it remains consistent with established performance standards.
• Regular Review: Have procedures in place for periodic reviews of AI outputs to confirm ongoing validation.
• Change Management: Document any AI system updates or parameter modifications, revising validation metrics as required.

System Security and Access Controls

Security is paramount, especially given AI systems' interconnectedness:

• User Access: Implement role-based system access that tracks user actions and limits operations to authorized personnel only.
• Security Incidents: Establish a protocol for detecting and responding to security breaches or suspicious activities involving AI tools.
• Multifactor Authentication: Use multifactor authentication to limit access to AI systems, especially those handling or generating critical regulatory data.

Training and SOPs

Ensure all personnel who interact with AI systems are adequately trained and have relevant Standard Operating Procedures (SOPs) at their disposal:

• User Training: Regular training sessions should be held to update team members on new AI systems, changes in regulations, and security protocols.
• Procedure Documentation: Document all processes involving AI tools, ensuring SOPs are comprehensive and regularly updated to reflect changes in compliance requirements.

In summary, compliance with 21 CFR Part 11 when implementing AI tools in pharmaceutical and CDMO operations is multifaceted, requiring attention to electronic records, signatures, data integrity, validation, security, and personnel training. Adhering to this checklist will not only facilitate compliance but also enhance the robustness and credibility of your AI systems in regulated environments.

See how ComplianceGxP handles 21 CFR Part 11 compliance for pharma and CDMO teams: See it in action →